HFSA Virtual Board Certification Review 2021

July 16, 2021 - July 18, 2021 | Virtual

Program

The HFSA Virtual Board Certification Review 2021 will be comprised of renowned heart failure experts presenting curriculum that has been tailored to the actual ABIM examination blueprint. The course will take place over three (3) days (July 16-18, 2021) and include the components outlined below. Check back soon for preliminary agenda, Advance Program, and more!

Download the Advance Program >>

Program Components

The program will be made up of the following components to allow attendees greater access to the content.

Pre-Recorded Webinar Series: Heart Failure Fundamentals

This pre-recorded, ondemand webinar series features the basics and can be completed at the attendee's convenience. Coming soon!

Virtual Meeting

A three day virtual meeting (July 16-18, 2021) delivered by top experts in the field. Sessions will be available to download within 48 hours of the session date. Coming soon!

Faculty "Office Hours"

Post-meeting, virtual livestream Q&A panel taking place on Friday, October 1, from 4:00 PM - 5:00 PM ET to allow attendees to ask follow-up questions.

Intended Audience

The HFSA Virtual Board Certification Review 2021 is designed for physicians who are preparing to take the ABIM Advanced Heart Failure & Transplant Cardiology Maintenance of Certification Exam or heart failure specialists seeking an in-depth review in heart failure.

Learning Objectives

Upon completion of the activity, participants will demonstrate improved competence and ability to: 

For the Certification Examination in Advanced Heart Failure and Transplant Cardiology:

  1. Identify gaps in knowledge about advanced heart failure and transplant cardiology
  2. Focus study efforts on filling identified knowledge gaps
  3. Practice for the certification examination with ABIM-style multiple-choice test questions

For Clinical Practice:

  1. Describe the epidemiology of heart failure, including environmental factors, and implement strategies for the prevention of heart failure
  2. Describe the pathophysiology of heart failure, including normal physiology and compensatory and maladaptive mechanisms
  3. Assess and follow the patient with acute or advanced heart failure, using non-invasive and invasive tests and biomarkers.
  4. Implement guideline-based therapy for patients with chronic heart failure, including pharmacologic agents; non-pharmacologic options, such as diet and exercise; and implantable devices
  5. Implement appropriate care strategies for patients undergoing chemotherapy or with pulmonary hypertension, heart failure with preserved ejection fraction, or cardiorenal syndrome.
  6. Manage comorbidities in patients with chronic heart failure, including sleep disordered breathing, anemia, and depression
  7. Implement strategies for effective disease management of the patient with advanced heart failure, including palliative care and transition to outpatient care
  8. Provide peri-operative management of heart failure patients undergoing cardiac transplantation or implantation of a mechanical circulatory device

Concise presentations by national experts will focus on blueprint content.

OnDemand Webinars: Heart Failure Fundamentals

Each webinar is 30 minutes in length. This series is available to all registered attendees in the online meeting platform under the OnDemand tab to be completed at the attendee's convenience.

Title

Speaker
Heart Failure Epidemiology and Risk Factors      Sadiya Kahn
Pathophysiology I: Cellular and Energetic Considerations Daniel Burkhoff
Pathophysiology II: Hemodynamic, Structural, and Neurohormonal Considerations Daniel Burkhoff
Diagnosis and Clinical Assessment Mark Drazner
Cardio-Oncology for the HF Boards Bonnie Ky
Clinico-Pathologic Correlates in HF / Images for the HF Boards Jon Lomasney
Statistics for the HF Boards Brian Claggett 
Virtual Meeting Details

The virtual meeting dates will take place July 16-18. Attendees should anticipate being online for the full sessions to maximize their learning potential. To attend a session on a virtual meeting day, click on the “Sessions” tab in the online platform.

If a participant is unable to participate live, the ondemand recordings of the sessions will be available within 48 hours of the session date on the “OnDemand” tab of the online platform. 

Scroll down to see the full agenda, and look below for the basic outline on days and topics. 

All sessions below are listed in Eastern Standard Time.                                                                                                                                       

            

Date

            
            

Livestream Times

            
            

Topics

            
            

Day #1 | Friday, July 16

            
            

3:00 PM – 6:20 PM EST

            
            
  • Cardiac Transplantation
  • Q&A Panel I
Day #2 | Saturday, July 17 11:00 AM – 8:00 PM EST
  • Keys in HF Management
  • Specific HF Syndromes
  • Q&A Panel II
Day #3 | Sunday, July 18 11:00 AM – 5:30PM EST
  • Shock/MCS
  • Special Topics in HF
  • Q&A Panel III
Faculty "Office Hours"

A post-meeting, virtual livestream Q&A panel to allow attendees to ask last-minute questions prior to the examination will take place Friday, October 1, 2021 from 4:00 PM - 5:00 PM ET. Faculty "Office Hours" will be live; therefore, attendees are encouraged to be available during these hours to engage in Q&A as final prep for the exam. More information coming soon.

Additional Bonus Features

In addition to the core program components, attendees will have access to the following: 

  • A question bank - updated for 2021!
  • Recommended reading list
  • Live polling, Q&A, and chat features available during the livestream days
  • Chat with fellow attendees and faculty throughout the course of the meeting

The question bank and recommended reading list will be available in the "Attendee Resources" tab of the online platform. 

Program Agenda

All sessions are listed in Eastern Standard Time.

03:00 pm - 03:20 pm

Welcome and HFSA Introduction 

Akshay Desai

John Barnes, HFSA CEO

03:20 pm - 03:50 pm

Advanced Heart Failure:  Defining the Phenotype and Patient Selection for Advanced Therapies

Nancy Sweitzer

03:50 pm - 04:20 pm

Immunology: The Basics, PRA, Sensitization, Crossmatch

Sean Pinney

04:20 pm - 04:50 pm

Rejection: Cellular and Antibody Mediated

Sean Pinney

04:50 pm - 05:20 pm

Managing Immunosuppression and Drugs

Michelle Kittleson

05:20 pm - 05:50 pm

Heart Transplant, Clinical Outcomes and Complications

Michelle Kittleson

05:50 pm - 06:20 pm

Q&A Panel I

Akshay Desai, Maria Rosa Costanzo, Jonathan Rich, Nancy Sweitzer

11:00 am - 11:15 am

Welcome and Introductions

Akshay Desai

11:15 am - 11:45 am

Hemodynamics in HF I 

James Fang

11:45 am - 12:15 pm

Hemodynamics in HF II 

James Fang

12:15 pm - 12:45 pm

Drug Therapy for Chronic HF I: Focus on established therapies (ACE/ARB/Beta-blocker/MRA/Digoxin/Hydralazine+Nitrates)

Clyde Yancy

12:45 pm - 01:15 pm

Drug Therapy for Chronic HF II: Focus on newer therapies (Sacubitril/Valsartan, Ivabradine, SGLT2 inhibitors)

Mark Drazner

01:15 pm - 01:45 pm

Break

01:45 pm - 02:15 pm

HFpEF: Epidemiology, Risk Factors, Diagnosis, Management (for the boards)

Sanjiv Shah

02:15 pm - 02:45 pm

Pulmonary Hypertension

Jonathan Rich

02:45 pm - 03:15 pm

Management of Common Arrhythmias I - Atrial Fib and Flutter

Roderick Tung

03:15 pm - 03:45 pm

Management of Common Arrhythmias in HF II

Roderick Tung

03:45 pm - 04:15 pm

Device Therapy in Heart Failure I - Sudden Death Prevention

Wendy Tzou

04:15 pm - 04:45 pm

Device Therapy in Heart Failure II - CRT

Wendy Tzou

04:45 pm - 05:00 pm

Break

05:00 pm - 05:30 pm

Management of the Hospitalized HF Patient

Maria Rosa Costanzo

05:30 pm - 06:00 pm

Cardio Renal Failure Interactions in Heart Failure

Jeff Testani

06:00 pm - 06:30 pm

Specific Etiologies of HF I: Common Etiologies (CAD, ETOH, Peripartum, Myocarditis)

Akshay Desai

06:30 pm - 07:00 pm

Specific Etiologies of HF II: Inherited HF syndromes (including HCM, ARVC, and LVNC)

Jane Wilcox

07:00 pm - 07:30 pm

Specific Etiologies of HF III: Infiltrative Disorders and Restrictive Cardiomyopathy (Amyloidosis, Sarcoidosis, Hemochromatosis, Fabry)

Sanjiv Shah

07:30 pm - 08:00 pm

Q&A Panel II

Akshay Desai, Maria Rosa Costanzo, Jonathan Rich, Nancy Sweitzer

11:00 am - 11:15 am

Welcome and Introductions

Akshay Desai

11:15 am - 11:45 am

Cardiogenic Shock Management

Nancy Sweitzer

11:45 am - 12:15 pm

MCS I: Durable MCS Devices and Outcomes

Joseph Rogers

12:15 pm - 12:45 pm

MCS II: Temporary Support Devices and ECMO for the Boards

Jennifer Cowger

12:45 pm - 01:15 pm

MCS III: MCS Complications and Patient Management

Jennifer Cowger

01:15 pm - 02:15 pm

MCS IV: Interactive Shock and Device Management

Daniel Burkhoff, Jennifer Cowger, Joseph Rogers, Nancy Sweitzer

02:15 pm - 02:30 pm

Break

02:30 pm - 03:00 pm

Assessment of Functional Capacity including cardiopulmonary exercise testing 

Gregory Lewis

03:00 pm - 03:30 pm

Adult Congenital Heart Disease for the HF Specialist

Eric Krieger

03:30 pm - 04:00 pm

Issues in Chronic HF Disease Management (Biomarkers, Remote Monitoring, Lifestyle Interventions)

Akshay Desai

04:00 pm - 04:30 pm

Management of Valvular Heart Disease in Heart Failure (including functional MR, low gradient AS, tricuspid regurgitation)

Jane Wilcox

04:30 pm - 05:00 pm

Management of Comorbidities in Heart Failure - Diabetes, Sleep Disorders, Iron Deficiency/Anemia, COPD

Maria Rosa Costanzo

05:00 pm - 05:30 pm

Q&A Panel III

Akshay Desai, Maria Rosa Costanzo, Jonathan Rich, Nancy Sweitzer